Notably, three different types of glycoepitopes (glycan-only, glycopeptide, and shielded-peptide) expressed on tumor-specific MUC1, MUC5AC, and MUC16 can be recognized by monoclonal antibodies (mAb) and may serve as promising candidate target for anticancer ADC development (Brassard et al. 2022). This evidence concerns the gene MUC1 and neoplasm.